MarketBeat reported consensus rating for Hikma Pharmaceuticals, while Jefferies increased its target price and gave a buy rating. Berenberg Bank reaffirmed its buy rating, and Citigroup restated a buy rating.
4 reports, 3 independent
Updated Fri 00:00
No new developments lately
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MarketBeat reported consensus rating for Hikma Pharmaceuticals, while Jefferies increased its target price and gave a buy rating. Berenberg Bank reaffirmed its buy rating, and Citigroup restated a buy rating.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Hikma expands branded medicine markets into Middle East and North Africa.1 source
Analyst rating updates for Hikma Pharmaceuticals from Jefferies, Berenberg Bank, and Citigroup.1 source
Keep exploring
The entities involved
-
Hikma Pharmaceuticals
UK-headquartered pharmaceutical company
Nothing else this week.
-
MarketBeat
American personal finance blog
-
Jefferies Financial Group
American financial services company
-
Berenberg Bank
German private bank based in Hamburg
Related events
- MarketBeat provided consensus ratings and target prices regarding Duke Capital Limited on August 12, 2026.
- MarketBeat is reporting on consensus ratings for Aehr Test Systems, a company whose stock trades on the Nasdaq exchange.
- MarketBeat reported consensus ratings and target prices for Deep Fission Inc., which received a strong-buy rating from Benchmark.
- Needham & Company raised its price objective and issued a buy rating for Ceragon Networks, with MarketBeat reporting consensus data.
- MarketBeat reported the stock's average rating as Benchmark and Jefferies reiterated buy ratings for Bright Minds Biosciences Inc.